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Malignant esophageal tumors are exceedingly rare in children and adolescents. We present 3 cases of
esophageal adenocarcinoma (AC) and squamous cell carcinoma (SSC) in patients 21 years of age who
were treated at our institution between 1950 and 2015. We also undertook an analysis of those cases,
combined with cases from a review of the literature, to examine patient demographics, disease char-
acteristics, and outcomes. We identiﬁed one patient with AC and two patients with SCC treated at our
institution, as well as 19 cases of AC (median age 16) and 23 cases of SCC (median age 15) reported in the
literature. Male predominance was noted at a ratio of 2.2 to 1. Dysphagia, weight loss, and anemia were
the most common presenting symptoms for both entities. Approximately 84% of AC tumors were located
in the distal esophagus and gastroesophageal junction whereas SCC tumors were distributed evenly
throughout esophagus. Metastatic disease at presentation was found in 68.4% of patients with AC
compared to 30.4% of those with SCC. Survival was not signiﬁcantly different between SCC and AC (P ¼
0.36), between genders (P ¼ 0.13), and between patients treated with surgery vs. multimodality therapy
(P ¼ 0.15). Metastasis, however, predicted worse outcome (P ¼ 0.0019). We found that adolescent AC and
SCC show characteristics similar to such tumors when presenting in adults. Though extremely rare in the
adolescent population, these malignant diseases should always be ruled out when young patients pre-
sent with a short history of dysphagia with signs of clinical deterioration.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Malignant esophageal tumors are the sixth leading cause of
death from cancer worldwide [1], with a peak prevalence between
35 and 64 years of age [1]. The presentation of an esophageal
tumor in children and adolescents is an exceedingly rare event.
Between 1973 and 2008, the Surveillance, Epidemiology, and End
Results (SEER) program identiﬁed only nine malignant esophageal
tumors in patients under age 20 [2]. The largest series was
presented by Kumar et al., in 1992 with four cases of squamous cell
carcinoma (SCC) and three of adenocarcinoma (AC) with the oldest
patient being 19 years of age [3]. With the report of three new
cases of our own and an extensive literature review, we aim to
contribute to the general understanding of these rare childhood
tumors.þ1 212 717 3373.
lia).
Inc. This is an open access article u1. Patients and methods
The review was conducted under an Institutional Review Board
waiver in accordance with the Health Insurance Portability and
Accountability Act regulations. All patients 21 years and younger
with AC and SCC treated in our institution between 1950 and 2015
were reviewed. Histopathology diagnosis was conﬁrmed by the
pathology service of our institution.
The international literature was reviewed for reports on malig-
nant tumors of the esophagus in patients under the age of 21 years
using the U.S. National Library of Medicine (www.pubmed.gov).
Search terms used: cancer, adenocarcinoma, squamous cell
carcinoma, esophagus, and children, childhood, child, pediatrics.
Publications in languages other than English were professionally
translated.
All cases of AC and SSC identiﬁed at our institution and in the
literature were analyzed for age at presentation, gender, presentingnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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T.M. Theilen et al. / J Ped Surg Case Reports 5 (2016) 23e2924symptoms, preexisting conditions, tumor histology, tumor location,
tumor differentiation, metastatic disease, treatment, and outcome.
Only reports with complete information on the histopathology
subtype of the tumor were included in later analysis. Survival was
analyzed using the Kaplan-Meiermethod, and the log-rank test was
used.
2. Results
We identiﬁed one patient with AC and two patients with SCC of
the esophagus treated at our institution. One 21-year-old male
presented with a poorly differentiated AC of the distal esophagus.
No Barrett’s esophagus was reported in the endoscopy histologic
report sections of the endoscopy or in the previous history. He died
2.2 months after chemotherapy with liver, vertebral, brain and
lymph node metastasis (Table 1). An 18-year-old male was treated
with palliative therapy for late stage SCC of themid-esophagus with
metastasis to lung, liver, diaphragm and lymph nodes. He died 11
months after ﬁrst presentation. The other patient with aTable 2
Patient characteristics of esophageal adenocarcinoma and squamous cell carcinoma
in patients 21 years and younger.
AC SSC Overall
Number of cases
Absolute (percent) 19 (45.2%) 23 (54.8%) 42 (100%)
Median age
Years (range) 16 (8e21) 15 (8e21) 15 (8e21)
Sex distribution
Male: Female 5.3: 1 1.3: 1 2.2: 1
Presenting symptoms
Dysphagia 15 (78.9%) 20 (87.0%) 35 (83.3%)
Weight loss 9 (47.4%) 14 (60.9%) 23 (54.8%)
Anemia 6 (31.6%) 8 (34.8%) 14 (33.3%)
Dehydration 4 (21.1%) 5 (21.7%) 9 (21.4%)
Nausea 3 (15.8%) 5 (21.7%) 8 (19.0%)
Epigastric or retrosternal
pain/burning
2 (10.5%) 4 (17.4%) 6 (14.3%)
Gastroesophageal reﬂux 5 (26.3%) e 5 (11.9%)
Vomiting 3 (15.8%) 2 (8.7%) 5 (11.9%)
Hematemesis 2 (10.5%) e 2 (4.8%)
Recurrent pneumonia e 1 (4.3%) 1 (2.4%)
Hematochezia 1 (5.3%) e 1 (2.4%)
Constipation 1 (5.3%) e 1 (2.4%)
Odynophagia e 1 (4.3%) 1 (2.4%)
Other conditions
Barrett’s esophagus 6 (31.6%) e 6 (14.3%)
Cigarette smoking 3 (10.5%)a 2 (8.7%)c 5 (11.9%)
Spinal palsy 3 (15.8%)a e 3 (7.1%)
Caustic injury e 3 (13.0%)d 3 (7.1%)
Previous surgery 1 (5.3%)e 1 (4.3%)f 2 (4.8%)
Previous cancer treatment e 1 (4.3%)g 1 (2.4%)
Hiatal hernia 1 (5.3%) 1 (4.3%)b 2 (4.8%)
HP positive gastritis 1 (5.3%) e 1 (2.4%)
Overweight 1 (5.3%)h e 1 (2.4%)
Foreign body ingestion 1 (5.3%)a 1 (2.4%)
Esophageal HPV-16 infection e 1 (4.3%) 1 (2.4%)
Factor VIII deﬁciency 1 (5.3%)a e 1 (2.4%)
Polycystic kidney disease and
vesicoureteral reﬂux IV
e 1 (4.3%)i,b 1 (2.4%)
Goiter with hyperthyroidism e 1 (4.3%)b 1 (2.4%)
None 7 (36.8%) 14 (60.9%) 21 (50.0%)
AC ¼ Adenocarcinoma, SCC ¼ Squamous cell carcinoma, HP ¼ Helicobacter pylori,
HPV-16 ¼ Human papillomavirus 16.
a Patients with Barrett’s esophagus within this group.
b Same patient.
c 3- and 5-year history of cigarette smoking.
d One case of lye ingestion and two cases of ingestion of an unknown agent.
e Esophageal atresia repair in infancy.
f Gastrostomy for trichobezoar removal.
g Surgery and chemotherapy for osteosarcoma.
h BMI ¼ 26.7 kg/m2.
i Chronic renal failure.
T.M. Theilen et al. / J Ped Surg Case Reports 5 (2016) 23e29 25moderately differentiated SCC of the mid-esophagus was a 21-year-
old female who received neoadjuvant chemo- and radiotherapy
followed by an Ivor Lewis esophagectomy. She was still alive after a
64-month follow-up period without any signs of recurrent disease.
A total of 19 cases of AC [3e15] and 21 of SCC [3,15e26] in pa-
tients younger than 21 years were identiﬁed in the international
literature (Appendices A and B). One of the patients with SCC was
part of an epidemiologic study for which no speciﬁc patient data
could be retrieved, and one AC case report was part of a journal’s
correspondence section with no further objective validation of
histology [27,28]. These patients were excluded from our study.
Including our own cases, we accumulated a total of 19 cases of AC
and 23 cases of SCC for further analysis.
Table 2 presents characteristics of this patient cohort. The
median age at presentation was 15 years (range, 8e21 years). The
youngest patients to present with an AC and SCC were both 8 years
old [10,20]. All other patients (40/42 patients [95.2%]) presented in
the second decade of life. With respect to sex distribution by tumor
entity, AC predominantly occurred in males (ratio, M:F ¼ 5.3:1),
whereas the incidence of SCC was almost evenly distributed
between the sexes (ratio, M:F ¼ 1.3:1).
In 18 of 42 reports (AC n ¼ 6, SCC n ¼ 12), the time to presen-
tation after the onset of ﬁrst symptoms was documented. Patients
presented after a mean period of 3.1 months (2.8 months)
following onset of ﬁrst symptoms. Presenting symptoms of all 42
patients are listed in Table 2. Dysphagia (35/42 patients [83.3%]),
weight loss (23/42 patients [54.8%]), anemia (14/42 patients
[33.3%]), dehydration (9/42 patients [21.4%]), and nausea (8/42
patients [19.0%]) were the leading presenting symptoms for both
AC and SCC (Table 2).
In review of all reports on AC, authors reported other preexisting
conditions prior to the onset of esophageal cancer in their patients.
These were spinal palsy, tobacco use, esophageal atresia repair,
hiatal hernia, overweight, previous foreign body ingestion, or Factor
VIII deﬁciency. In 6 of 19 patients with AC (31.6%) the existence of
Barrett’s esophagus in areas surrounding the tumor was described
[6,8,13] (Table 2). In the remaining 13 cases, no information was
provided about the presence or absence of Barrett’s esophagus.
Pre-existing conditions among patients with SCC included his-
tory of caustic injury, tobacco use, gastric surgery for trichobezoar
removal, chemotherapy for osteosarcoma, esophageal HPV-16Table 3
Tumor characteristics of esophageal adenocarcinoma and squamous cell carcinoma
in patients 21 years and younger.
AC, n ¼ 19 SSC, n ¼ 23 Overall, n ¼ 42
Tumor location
Proximal third e 7 (30.4%) 7 (16.6%)
Middle third 4 (21.1%) 8 (34.8%) 12 (28.6%)
Distal third 9 (52.6%) 8 (34.8%) 17 (40.5%)
GE junction 6 (31.6%) e 6 (14.3%)
Unknown e e e
Tumor differentiation
Well 2 (10.5%) 10 (43.5%) 12 (28.6%)
Moderate 2 (10.5%) 3 (13.0%) 5 (11.9%)
Poor 9 (52.6%) 2 (8.7%) 11 (26.2%)
Unknown 6 (31.6%) 8 (34.8%) 14 (33.3%)
Tumor dissemination
No metastatic disease 4 (21.1%) 11 (47.8%) 15 (35.7%)
Metastatic disease 13 (68.4%) 7 (30.4%) 20 (47.6%)
Lymph nodes 9 (69.2%) 5 (71.4%) 14 (70.0%)
Lung/pleura 1 (7.7%) 3 (42.9%) 4 (20.0%)
Liver 4 (30.8%) 2 (8.7%) 6 (30.0%)
Brain/dura mater 2 (15.4%) e 2 (10.0%)
Bone 1 (7.7%) e 1 (5.0%)
Diaphragm e 1 (14.2%) 1 (5.0%)
Unknown 2 (10.5%) 5 (21.7%) 7 (16.6%)
AC ¼ Adenocarcinoma, SSC ¼ Squamous Cell Carcinoma, GE ¼ Gastroesophageal.infection, hiatal hernia, polycystic kidney disease, vesicoureteral
reﬂux disease IV with chronic renal failure, and goiter with
hyperthyroidism (Table 2). In 3 patients, SCC after caustic injury
(due to lye ingestion in one case and due to unknown agents in 2
cases) occurred after a latency of 1, 10 and 12 years, respectively,
after ingestion [17,21,29].
In 15 of 19 (84.2%) patients, AC occurred in the distal esophagus
and in the gastroesophageal junction (GEJ), whereas the cases of
SCC showed an even distribution within the esophagus (Table 3).
Recognizing that not all reports mentioned the histological differ-
entiation, AC showed a higher tendency to be poorly differentiated
compared to SSC (Table 3).
AC had a higher frequency of metastasis (n ¼ 13 of 19 [68.4%])
compared to SCC (n ¼ 7 of 23 [30.4%]). Lymph nodes were the most
common metastatic site with positive nodes found along the
esophagus, above the clavicle, along the aorta, the vena cava, at the
celiac trunk, the lesser gastric curvature, and around the pancreas
and the renal hilum. Only patients with AC developed brain and
bone metastases (Table 3).
Survival was reported in 18 of 23 cases of SCC and in all 19 cases
of AC. At the time of writing this report, 9 patients with SCC have
died, either of disease (n ¼ 6) or in relation to treatment (n ¼ 3).
Among 12 reported deaths among patients with AC, 11 were
disease-related and 1 was treatment-related. Data on follow-up
time and survival were provided for 12 SCC and 17 AC patients. For
these patients the median survival time was 14 months for SCC and
9 months for AC (including patients with treatment-related deaths,
Fig. 1). The overall survival between SCC and AC was not signiﬁ-
cantly different (P ¼ 0.3683).
In the analysis of treatment strategies, we identiﬁed 6 patients
(SCC n¼ 1, AC n¼ 5) treated with surgery plus chemotherapy. All of
these patients were still alive compared to only 5 of 9 patients
treated with surgery alone (SCC n ¼ 4, AC n ¼ 5).3. Discussion
Malignant esophageal tumors are extremely rare in children and
adolescents. The majority of cases reported in the literature consist
of SCC [3,15e27,30e32] and AC [3e15]. Other malignant esophageal
tumors reported in the literature consist of synovial cell sarcoma
[33e35], melanoma [36], and “lymphosarcoma” (presumably lym-
phoma, according to current classiﬁcations) [37]. At our institution
we treated one patient with an AC and two patients with SCC.
Almost all patients presented during the second decade of life at
a median age of 15 years (range, 8e21). The two patients youngerFig. 1. Overall survival according to histology subtype. The median survival period was
9 months for adenocarcinoma (AC; n ¼ 17) and 14 months for squamous cell carcinoma
(SCC; n ¼ 12) (P ¼ 0.3683).
T.M. Theilen et al. / J Ped Surg Case Reports 5 (2016) 23e2926than age 10 showed no special characteristics other than the early
onset of disease. In parallel to manifestation in adulthood, AC pre-
dominated amongmale patients (M:F¼ 5.3:1) and SCCwere evenly
distributed between the genders [38].
The time to presentation after onset of complaints was very
short with an average of 3.1 months (2.8 months). This interval is
exceedingly shorter than the time to presentation of patients with
benign esophageal lesions, which are often tolerated for many
months and even years [39]. Dysphagia was the leading symptom
followed by signs of clinical deterioration (weight loss, anemia,
dehydration). However, benign esophageal lesions, such as leio-
myomatosis, seem to present with respiratory symptoms, pain and
vomiting [40].
Causes for the onset of esophageal malignancies in teenage years
are yet undeﬁned. In general, the same pathogenic factors for adult
esophageal carcinogenesis are assumed to be true for the younger
age group [25,41,42]. Among the reviewed patients with AC, 6 pa-
tients (31.6%) were diagnosed with Barrett’s esophagus [6,8,13].
This number is likely to be higher since not all patients had been
evaluated for this condition. Interestingly, about 63.2% of all AC
patients had pre-existing conditions such as spinal palsy, hiatal
hernia, esophageal atresia repair in infancy, history of foreign body
ingestion, smoking, and obesity, all of which can be can be associ-
ated with gastroesophageal reﬂux disease (GERD), a risk factor for
Barrett’s esophagus [5,7,8,15].
Ingestion of caustic agents and history of smoking, two well-
deﬁned pathogenic factors for SCC, were only reported in ﬁve cases
[13,17,21,29,32]. SCC developed 1, 10 and 12 years after caustic
injury and after 3 and 5 years of cigarette smoking. Twenty patients
(47.6%) developed metastasis. This rate is identical to that among
adults, who also presented with metastatic disease in about 50% of
cases [38].
In general, the failure to diagnose a malignant disease early is a
known reason for poor prognosis. Including those patients identiﬁed
in our literature search, data on follow-up time and survival were
available for 17 patients with AC and 12 with SSC. For those patients,
the median survival time was 9 months for AC and 14 months for
SCC. Among adults with AC or SCC to the esophagus, the median
survival time is reported to be between 13 and 19 months [38].
When young patients present with a (short) history of dysphagia
a mediastinal process should be ruled out among other causes.
Work-up should include blood examination, x-ray of the thorax, CT
and/or MRI scan. Ultimately, biopsy is needed to deﬁne the histol-
ogy if a mediastinal mass is present. Due to the rarity of esophageal
cancer in children, treatment is based on principles used in adults.
Complete surgical resection with wide margins and extended
lymphadenectomy is the gold standard of surgical therapy. Some
authors advocate the use of adjuvant chemotherapy leading to
prolonged periods of remission among adults [38,43]. However, no
common treatment strategies are established in children.
4. Conclusions
With the presentation of our three new cases of childhood
esophageal cancer and a comprehensive review of the literature, we
aim to contribute to the general understanding of this rare disease
in the young. It is important for clinicians to consider a malignant
esophageal process in children who present with a short history of
dysphagia with signs of rapid deterioration including weight loss,
dehydration, and anemia.
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Appendix A. Table A
Esophageal adenocarcinoma in children and adolescents (<21 years of age) reported in the literature.
Author/year Age/sex Esophageal
location (in thirds)
Histologic
differentiation
Metastasis Therapy Follow-up period
(months)
Follow-up
status
Comments
Elliot, 1983 14/M Distal Moderate Lymph node, bone Esophagogastrectomy, esophagostomy 7 DOD
Al Hilou, 1984 15/M Middle Poor Lymph node Palliative endo-esophageal stent 5 DOD
Bright, 1986 20/M Distal Poor Lymph node Sub-total esophagectomy,
esophagogastrostomy, adjuvant
chemotherapya
3 NED Patient with factor VIII deﬁciency
Hoeffel, 1989 11/M Distal Not noted Not noted Esophagectomy 0 died Died of aortic rupture
14/M Distal Well Liver Distal 2/3rd esophagectomy, prox.
gastrectomy
24 DOD Late liver metastasis
Adzick, 1989 20/F GEJ Moderate No Distal esophagectomy, prox. gastrectomy,
transverse colon interposition
12 NED EA repair in infancy, tumor distal to site of
EA repair
Kumar, 1992 19/M Middle Poor Lung Palliative presternal gastric pull-up 4 DOD
18/M Middle Well Brain Palliative radiotherapy 2 DOD
17/M Distal Poor No Partial esophagectomy
esophagogastrostomy, adjuvant
chemotherapyb
12 NED
Hassall, 1993 17/M Distal Not noted No Total esophagectomy, gastric pull-up 36 NED Patient with spastic quadriplegia
15/M Distal Not noted Liver Not noted not noted DOD Patient with cerebral palsy
19/M Distal Not noted Lymph node Not noted not noted DOD Patient with cerebral palsy
McGill, 1993 16/F GEJ Poor Lymph node Esophagogastrectomy and
gastroesophagostomy, adjuvant
chemotherapyc
30 NED
Gangopadhyay, 1997 8/M Middle Not noted Not noted Therapy refused 6 DOD
Sasaki, 1999 11/F GEJ Not noted Lymph node Endoscopic polypectomy, distal
esophagectomy, proximal gastrectomy and
jejunum interposition, chemotherapya
11 NED
Zotter, 2001 16/M GEJ Poor No Neo-adjuvant chemotherapy,d
esophagogastrectomy,
esophagojejunostomy
16 NED
Radhika, 2009 12/M GEJ Poor Lung Neo-adjuvant chemotherapye 9 DOD Patient refuses surgery after tumor progress
under chemotherapy
Issaivanan, 2012 18/M GEJ Poor Liver, lymph node Neo-adjuvant chemotherapyf 6 DOD Tumor progress under chemotherapy
M ¼ male, F ¼ female, GEJ ¼ Gastroesophageal junction, TE ¼ tracheo-esophageal, EA ¼ esophageal atresia, ALL ¼ acute lymphocytic leukemia, DOD ¼ died of disease, NED ¼ no evidence of disease.
a Chemotherapeutic agents not speciﬁed.
b 5-ﬂuorouracil, adriamycin, mitomycin C (6 cycles).
c Etoposide, doxorubicin, cisplatin.
d Methotrexate, 5-ﬂuorouracil, cisplatin, etoposide, paclitaxel.
e 5-ﬂuorouracil, cisplatin (8 cycles).
f Cisplatin, irinotecan (4 cycles) then capecitabine, docetaxel.
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Appendix B. Table B
Esophageal squamous cell carcinoma in children and adolescents under the age of 21 reported in the literature.
Author/year Age/sex Esophageal location
(in thirds)
Histologic
differentiation
Metastasis Therapy Follow-up period
(months)
Follow-up
status
Comments
Kaufmann, 1896 21/F Proximal Not noted Not noted Tumor resection Not noted Died Death secondary to aspiration pneumonia
Kinnman, 1968 15/M Proximal Well No Temporary gastrostomy 0 Died Lye ingestion at the age of 3, death secondary to
tumor tracheo-esophageal ﬁstula and
bronchopneumonia
Oberiter, 1976 12/F Proximal Not noted Lymph node Radiotherapy 6 DOD Tumor unresectable
Singh, 1979 14/M Middle Not noted Lymph node Palliative gastrostomy Not noted DOD Tumor unresectable
Soni, 1980 8/F Middle Well Lung Radiotherapya Not noted Not noted Tumor unresectable, transient tumor regression
after irradiation
Dewar, 1988 20/F Middle Not noted Not noted Not noted Not noted Not noted
Shahi, 1989 14/M Proximal Well No Radiotherapyb 0 AWD Excellent response to radiotherapy, patient did
not return for surgery
Schettini, 1989 11/F Proximal Not noted Not noted Esophagectomy with gastrostomy and cervical
esophagostomy
3 DOD Possibly caustic injury with one year of age, R1
resection and rapid tumor recurrence
Kumar, 1992 18/F Middle Well No Neo-adjuvant radiotherapy,c total
esophagectomy, esophagogastrostomy
18 NED
16/F Distal Poor No Neo-adjuvant chemotherapy,d radiotherapy,c
total esophagectomy, esophagogastrostomy
14 DOD Poor response to chemotherapy, local
recurrence after 14 months
14/M Proximal Well No Radiotherapyb 6 Lost to follow-up
18/M Middle Poor No Chemotherapyd Lost to follow-up AWD Excellent response to chemotherapy, patient
did not return for radiotherapy
Aryya, 1993 10/M Distal Well Not noted Not noted Lost to follow-up Not noted Patient did not return for radiotherapy
Karwasra, 1999 17/M Distal Moderate Lymph node Esophagectomy, esophagogastrostomy 6 NED
Allam, 2000 15/F Distal Well No Esophagectomy and proximal gastrectomy,
esophagogastrostomy
9 NED
Semnani, 2005 20/M Middle Not noted Not noted 0 Died Died of cardiac arrest during surgery
Tampi, 2005 15/M Distal Well No Ivor Lewis esophagectomy, adjuvant
chemotherapye
20 NED Esophageal HPV-16 infection
Singh, 2010 16/F Distal Well No Partial esophagectomy and proximal
gastrectomy, esophagogastrostomy
14 NED Gastrostomy at age of 8 for trichobezoar
removal
Hedawoo, 2010 15/M Distal Well No Partial esophagus resection, fundus resection,
partial diaphragm resection, gastric tube
formation
Not noted NED
Jain, 2010 14/M Proximal Not noted Lymph node Radiotherapyf 5 Not noted
Issaivanan, 2012 14/M Distal Moderate Lung, liver Neo-adjuvant chemotherapy,g esophagectomy
with primary anastomosis
9 DOD Tumor progressed on chemotherapy and after
surgery
M ¼ male, F ¼ female, GEJ ¼ gastro-esophageal junction, EA ¼ esophageal atresia, ALL ¼ acute lymphocytic leukemia, DOD ¼ died of disease, NED ¼ no evidence of disease, AWD ¼ alive with disease.
a Tele-cobalt.
b 7000 cGy (35 fractions).
c 2500 cGy (5 fractions).
d Cis-platinum, methotrexate (2 cycles).
e Paclitaxel, 5-FU, cisplatin (4 cycles).
f No other treatment was speciﬁed.
g Paclitaxel, carboplatin (4 cycles).
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